$2.45 Billion is the total value of Artal Group S.A.'s 110 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| YMAB | Exit | Y MABS THERAPEUTICS INC | $0 | – | -50,000 | -100.0% | -0.04% | – |
| MRNS | Exit | MARINUS PHARMACEUTICALS INC | $0 | – | -500,000 | -100.0% | -0.05% | – |
| MNTA | Exit | MOMENTA PHARMACEUTICALS INC | $0 | – | -200,000 | -100.0% | -0.08% | – |
| FIXX | Exit | HOMOLOGY MEDICINES INC | $0 | – | -100,000 | -100.0% | -0.08% | – |
| CLVS | Exit | CLOVIS ONCOLOGY INCcall | $0 | – | -200,000 | -100.0% | -0.13% | – |
| VALE | Exit | VALE S Acall | $0 | – | -500,000 | -100.0% | -0.24% | – |
| FGEN | Exit | FIBROGEN INCcall | $0 | – | -150,000 | -100.0% | -0.26% | – |
| ANAB | Exit | ANAPTYSBIO INC | $0 | – | -150,000 | -100.0% | -0.35% | – |
| WYNN | Exit | WYNN RESORTS LTDcall | $0 | – | -100,000 | -100.0% | -0.37% | – |
| BLUE | Exit | BLUEBIRD BIO INCcall | $0 | – | -100,000 | -100.0% | -0.37% | – |
| CMTA | Exit | CLEMENTIA PHARMACEUTICALS IN | $0 | – | -850,000 | -100.0% | -0.37% | – |
| MDCO | Exit | MEDICINES COcall | $0 | – | -600,000 | -100.0% | -0.42% | – |
| MU | Exit | MICRON TECHNOLOGY INCcall | $0 | – | -400,000 | -100.0% | -0.47% | – |
| BMRN | Exit | BIOMARIN PHARMACEUTICAL INCcall | $0 | – | -200,000 | -100.0% | -0.63% | – |
| FCX | Exit | FREEPORT-MCMORAN INCcall | $0 | – | -2,000,000 | -100.0% | -0.76% | – |
| ALNY | Exit | ALNYLAM PHARMACEUTICALS INCcall | $0 | – | -300,000 | -100.0% | -0.81% | – |
| BGNE | Exit | BEIGENE LTDcall | $0 | – | -200,000 | -100.0% | -1.04% | – |
| MS | Exit | MORGAN STANLEYcall | $0 | – | -1,500,000 | -100.0% | -2.20% | – |
| WFC | Exit | WELLS FARGO CO NEWcall | $0 | – | -1,500,000 | -100.0% | -2.56% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AGENUS INC | 42 | Q3 2023 | 1.9% |
| IRONWOOD PHARMACEUTICALS INC | 42 | Q3 2023 | 0.3% |
| ALNYLAM PHARMACEUTICALS INC | 37 | Q3 2023 | 5.1% |
| LEXICON PHARMACEUTICALS INC | 34 | Q3 2023 | 20.6% |
| AMICUS THERAPEUTICS INC | 30 | Q3 2023 | 2.7% |
| BEIGENE LTD | 28 | Q3 2023 | 7.4% |
| BK OF AMERICA CORP | 28 | Q1 2021 | 4.3% |
| SAGE THERAPEUTICS INC | 28 | Q2 2023 | 1.9% |
| AGIOS PHARMACEUTICALS INC | 28 | Q2 2020 | 1.1% |
| NEKTAR THERAPEUTICS | 27 | Q2 2020 | 1.3% |
View Artal Group S.A.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| WEIGHT WATCHERS INTERNATIONAL INC | February 13, 2015 | 29,443,300 | 51.9% |
View Artal Group S.A.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-05-17 |
| 4 | 2024-05-14 |
| 13F-HR | 2024-05-13 |
| 4 | 2024-03-25 |
| 4 | 2024-03-13 |
| 4 | 2024-02-29 |
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-13 |
| 4 | 2023-10-16 |
| 13F-HR | 2023-08-11 |
View Artal Group S.A.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.